ADT plus apalutamide before and after surgery significantly improved metastasis-free survival

CHICAGO — The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with localized high-risk prostate cancer, according to…

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long…